• Dyadic International entered a collaboration with BRIG BIO and Strive Nutrition to develop and commercialize precision-fermented bovine alpha-lactalbumin for U.S. nutrition markets.
• The partners will use the Dapibus production platform to develop the protein for Strive’s FREEMILK platform and other nutrition products.
• Initial commercial availability is targeted at more than 10 metric tonnes, subject to successful development, regulatory readiness, quality qualification and definitive agreements.
• Completion of the self-affirmed GRAS process is targeted for early 2028, ahead of initial commercial availability.
• Longer-term production is targeted at more than 200 metric tonnes annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyadic International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100730PRIMZONEFULLFEED9874271) on November 10, 2026, and is solely responsible for the information contained therein.